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Objective: To investigate the expression of targeting protein for Xenopus kinesin-like
protein 2 (TPX2) in breast cancer tissue and to explore its role in proliferation, migra-
tion and invasion of breast cancer cells.
Methods: The mRNA and protein expressions of TPX2 in breast cancer tissue and cell
lines were assessed by quantitative RT-PCR and Western blot. The effect of TPX2 with
RNA interference on proliferation, invasion and migration of breast cancer cells was
observed by MTT and Transwell assays.
Results: Both mRNA and protein expressions of TPX2 were upregulated in breast
cancer tissues compared to tumor-adjacent tissue. TPX2 expression was also upregulated
in breast cancer cell lines, and the TPX2 interfered by small interfering RNA could inhibit
the proliferation, invasion and migration of breast cancer cells by inhibiting matrix
metalloproteinase-2 and matrix metalloproteinase-9.
Conclusions: Signiﬁcantly upregulated TPX2 expression is observed in breast cancer
tissue and cells, and contributes to promote the proliferation, migration and invasion of
breast cancer cells.1. Introduction
Breast cancer is the most common tumor in females [1].
Despite of development in sorts of advanced diagnostic
equipment and standardized treatment guideline including
surgery, radiotherapy, chemotherapy and hormonotherapy, the
prognosis of breast cancer is still not ideal [2]. The main
reason of lethality is the metasta of cancer cells [3,4]. Metasta
is a multi-step process, including proliferation, migration, in-
vasion, and clonal expansion by adherence to attachment point
[5]. However, the speciﬁc regulation mechanism still remains
unclear. Therefore, it is the key point in both discovering new
therapeutic target and improving prognosis of breast cancer to
search for new transferred molecular markers [6,7].Targeting protein for Xenopus kinesin-like protein 2 (TPX2)
is a prohibitin strictly regulated by cell cycle, with involvement
in microtubule-associated proteins formed by spindle apparatus
in mitosis, and was ﬁrst found by Heidebrecht in 1997 [8].
TPX2 is a microtubule-associated protein strictly regulated by
cell cycle which appears in G1-S phase of the cell cycle and
disappears after completement of mitosis [9]. In the phase of
mitosis [10], TPX2 is released through Ras-related nuclear
protein GTPase pathway and activated by phosphorylation of
Aurora A; TPX2 and Aurora A are mutually combined during
the spindle apparatus assembly. The structure destruction will
result in error in spindle apparatus assembly and abnormality of
chromosome will lead to incidence of tumor. There are also
researches showing that TPX2 plays an important role in DNA
damage stress and regulating g-H2AX signaling pathway. In
recent years, connection between TPX2 and incidence as well
as development of malignant tumor is becoming the focus of
researches [11]. More and more evidences show that the
abnormal expression of TPX2 is related to the invasion and
development of tumors. In many tumor tissues, abnormally
high expression of TPX2 has been conﬁrmed [12,13], such asopen access article under the CC BY-NC-ND
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and liver cancer [18]. In addition, TPX2 is also conﬁrmed to be
a molecular marker for unfavorable prognosis in patients.
Meanwhile, as a pro-cancer gene, TPX2 can upregulate
expression of matrix metalloproteinases (MMP) family through
activating PI3K/Akt pathway in colon cancer. The lately
research shows that inhibiting the TPX2 expression through
downregulating expressions of MMP2 and MMP9 can inhibit
the invasion of liver cancer cells. However, the function of
TPX2 in breast cancer is still unclear and its speciﬁc regulation
mechanism in tumor development has not been well studied.
The present study aims to investigate the expression of TPX2
in breast cancer tissue and cells and its function in the cell
invasion and migration.
2. Materials and methods
2.1. Pathological tissues and cell lines
The female cases with no access to radiotherapy and
chemotherapy before surgery were included in this study. The
age range was between 29 and 73 years with the median age of
54.8 years. Without the knowledge of clinical data about path-
ologic specimens, two pathologists conﬁrmed the specimens to
be breast cancer ones through independent double-blind method.
All the tissues were the fresh specimen tissues acquired after
surgery, which were transferred to liquid nitrogen for further
experiment. The consent was acquired from all the patients in
the study.
Human breast cancer cell lines MCF7 and SKBR3 were
cultured in dulbecco's modiﬁed eagle medium (DMEM) con-
taining 10% fetal bovine serum (FBS; Gibco). Cell line MDA-
MB-231 was cultured in L15 medium (Invitrogen) containing
10% FBS in an incubator with 5% CO2 and kept at 37 C. Cells
at logarithmic phase were used for further experiment.
2.2. Quantitative RT-PCR
The total RNA in breast cancer tissue and cells was extracted
by using TRIZOL kit (Invitrogen). The synthesis of cDNA was
operated according to the speciﬁcation of revertid ﬁrst strand
cDNA synthesis kit, namely, reverse transcription at 37 C for
30 min, inactivation of reverse transcriptase at 94 C for 2 min,
with b-actin gene as the internal reference. The ampliﬁed re-
action was conducted based on the speciﬁcation of SYBR
Premix Ex Taq™ Ⅱ. The reaction conditions were as follows:
94 C for 2 min, 94 C for 30 s, 72 C for 45 s, with 30 cir-
culation of ampliﬁcation; extension at 72 C for 10 min at last.
The results were analyzed with 2−DDCt to reduce deviation.
Three repeated holes were set for each sample and the experi-
ment was performed in triplicate. The primer sequence was as
follows: TPX2: sense 50-ACCTTGCCCTACTAAGATT-30,
antisense 50-ATGTGGCACAGGTTGAGC-30; b-actin: Sense
50-GAGCTACGAGCTGCCTGACG-30, Antisense 50-CCTA-
GAAGCATTTGCGGTGG-30.
2.3. Western blot assay
Total protein in liver cancer tissue and cells was extracted by
using RIPA lysis buffer (high intensity) (Beyotime Biotech-
nology, Beijing, China). The concentration of protein samplewas determined by bicinchoninic acid assay. A total of 60 mg
protein was added to each sample and transferred to PVDF
membrane after electrophoretic separation with 10% sodium
dodecyl sulfate-polyacrylamide gelelectrophoresis. The 5%
skimmed milk powder was used to seal the sample for 2 h, after
which the 5% bovine serum albumin/phosphate buffered saline
tween was added to dilute the TPX2 polyclonal antibody
(Abcam, ab134309, 1:1000) and b-actin polyclonal antibody
(Santa Cruz, sc-7210, 1:2000), and rabbit anti-MMP2 poly-
clonal antibody (sc-10736), rabbit anti-MMP9 polyclonal anti-
body (sc-10737), and kept at 4 C overnight. Tris buffered saline
(TBS) with tween (TBS, 0.1% Tween-20) was used to wash
membrane for 3 times with 5 min for each time. The horse radish
peroxidase marked second antibody (goat anti rabbit) was added
for incubation at room temperature for 2 h. TBS with tween
(TBS, 0.1% Tween-20) was used to wash membrane for 3 times
with 5 min for each time and ECL chemiluminescence reagent
was used for scotography.
2.4. Small interfering RNA (siRNA) transfection
The siRNA speciﬁc to TPX2 and control RNA were pur-
chased from Santa Cruz Biotechnology (USA). Cells were
inoculated in a 6-well plate (2 × 106/well). According to spec-
iﬁcation of lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA), the siRNA transfected cells were ﬁltrated to make the
optimum concentration of 100 nmol/L. Cells at logarithmic
phase were added into synthesized speciﬁc TPX2 siRNA and
control siRNA respectively. After 48 h of culture, total RNA and
protein were extracted and silencing effect was detected by using
RT-PCR and Western blot assays.
2.5. MTT assay
Effect of TPX2 after siRNA interference on proliferation of
breast cancer cells was detected by MTT assay (Sigma, St.
Louis, MO, USA). The total volume of 200 mL cells were
inoculated in a 96-well plate with 0.2 × 104 cells in each well. At
each time point, 20 mL 5 mg/mL MTT was added to wells for
incubation at 37 C for 4 h, after which 150 mL dimethyl sulf-
oxide was added to vibrate for 10 min. The optical density was
determined at 490 nm. All the experiments were conducted in
triplicate.
2.6. Cell invasion and migration by transwell assay
According to speciﬁcation of Costar Transwell, the Matrigel
which was frozen at −20 C was placed at 4 C overnight to melt
into liquid. The serum-free DMEM was added to dilute Matrigel
into 1 mg/mL on ice. After complete blending, it was added to
Transwell chamber with 100 mL for each well and was coated at
37 C for 1 h. Serum-free culture solution was used to wash for 3
times and then kept at 37 C for standby application. Cells at
logarithmic phase were used to transfect siRNA, and after 24 h
of culture, cells were collected and serum-free DMEM was used
to resuspend cells to make the cell concentration of 2.5 × 105/
mL. For the upper embedded culture chambers in the previously
coated Matrigel (invasion experiment) or uncoated Matrigel
(migration experiment), 100 mL cell suspension was added. For
the bottom culture chamber, 600 mL DMEM with 10% FBS was
added. Three repeated holes were set for each group. The
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liquid in chambers was ejected and cells on the internal surface
of chamber bottom were wiped with cotton swab, ﬁxed with
paraformaldehyde, stained with crystal violet, and rinsed with
phosphate buffered saline. The random 4 views were chosen for
each culture well under the light microscope, and the number of
cells in each view was counted.
2.7. Statistical analysis
Data were analyzed by using SPSS 18.0 software.
Measurement data were expressed as mean ± SD, and differ-
ences with P < 0.05 were considered to be signiﬁcantly
statistical.3. Results
3.1. Upregulated expression of TPX2 both in breast
cancer tissue and cells
To study the expression of TPX2 in breast cancer tissue and
cells, the mRNA and protein expressions of TPX2 were
analyzed by using quantitative RT-PCR and Western blot as-
says. It was found that the mRNA transcription level and
protein expression of TPX2 in breast cancer tissue were
signiﬁcantly higher than those in tumor-adjacent tissue
(Figure 1). The mRNA and protein expressions of TPX2 were
found to be signiﬁcantly higher in breast cancer cell lines
MDA-MB-231 and MCF7 than SKBR3 cells. All the results
suggested that TPX2 may have the carcinogenesis in breast
cancer.Figure 1. mRNA and protein expressions of TPX2 in breast cancer tissue and
A: Relative TPX2 mRNA expression in breast cancer tissue and tumor-adjacent
cancer cell lines by RT-PCR; C: Relative TPX2 protein expression in breast c
protein expression in different breast cancer cell lines by Western blot; NT: Tu3.2. Downregulation in TPX2 expression in breast
cancer cells by siRNA
Previous researches showed that TPX2 could promote the
formation and metasta of tumors. To study the role of TPX2 in
breast cancer, speciﬁc TPX2 siRNA was used to transfect MDA-
MB-231 and MCF7 cells, and interference efﬁciency was deter-
mined by quantitative RT-PCR and Western blot. As it can be
seen in Figure 2, speciﬁc siRNA could successfully downregulate
the expression of TPX2 in both MDA-MB-231 and MCF7 cells.
3.3. Inhibition of breast cancer cell proliferation by
downregulated TPX2
To verify the role of TPX2 in breast cancer, the effect of
downregulated TPX2 on proliferation of breast cancer cells was
determined by MTT assay. It was found that the proliferation of
breast cancer cells was signiﬁcantly inhibited by TPX2 which
was downregulated by siRNA (Figure 3).
3.4. Inhibition of breast cancer cell migration by
downregulated TPX2
To verify the effect of TPX2 in breast cancer cell migration, the
role of TPX2 downregulated by siRNA in breast cancer cell
migration was investigated in Transwell migration experiment. It
was found that downregulated TPX2 could inhibit the migration of
tumor cells (Figure 4), which suggested that TPX2 may play an
important role inmigration of breast cancer cells. Stainingof crystal
violet showed the migration of MDA-MB-231 and MCF7 cells
cultured for 48 h in Transwell chambers without Matrigel (100×).cell lines.
tissue by RT-PCR; B: Relative TPX2 mRNA expression in different breast
ancer tissue and tumor-adjacent tissue by Western blot; D: Relative TPX2
mor-adjacent tissue; T: Breast cancer tissue; *: P < 0.05.
Figure 2. Downregulation in expression of TPX2 in MDA-MB-231 and MCF7 cells by speciﬁc TPX2 siRNA.
A: Interference effect of siRNA on TPX2 in MDA-MB-231 and MCF7 cells by RT-PCR; B: Interference effect of siRNA on TPX2 in MDA-MB-231 and
MCF7 cells by Western blot; **: P < 0.05.
Figure 3. Effect of TPX2 downregulated by siRNA on proliferation of breast cancer cells.
A: Effects of downregulated TPX2 and control siRNA on proliferation of MDA-MB-231 cell by MTT assay; B: Effects of downregulated TPX2 and control
siRNA on proliferation of MCF7 cell by MTT assay; *: P < 0.05.
Figure 4. Effect of TPX2 downregulated by siRNA on breast cancer cell migration by Transwell assay.
A: MDA-MB-231 cell; B: MCF7 cell; *: P < 0.05.
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Figure 5. Effect of TPX2 downregulated by siRNA on breast cancer cell invasion by Transwell assay.
A: MDA-MB-231 cell; B: MCF7 cell; *: P < 0.05.
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downregulated TPX2
To verify the role of TPX2 in the breast cancer cell in-
vasion, the effect of TPX2 downregulated by siRNA on in-
vasion of breast cancer cells was determined by using
Transwell migration experiment. It was found that down-
regulated TPX2 could signiﬁcantly inhibit the migration of
breast cancer cells (Figure 5), suggesting that TPX2 may play
a key role in invasion of breast cancer cells. Staining of
crystal violet showed the invasion of MDA-MB-231 and
MCF7 cells cultured for 48 h in Transwell chambers with
Matrigel (100×).Figure 6. Expressions of MMP2 and MMP9 by Western blot.
A: MDA-MB-231 cell; B: MCF7 cell; *: P < 0.05.3.6. Inhibition of MMP2 and MMP9 by downregulated
TPX2
MMP plays a signiﬁcant role in the migration and invasion of
tumors, especially MMP2 and MMP9. To get to know more
about the role of TPX2 in downstream signaling pathway of
breast cancer cells, whether or not the expressions of MMP2 and
MMP9 were affected by TPX2 downregulated by siRNA was
determined. The results of Western blot showed that down-
regulated TPX2 could signiﬁcantly decrease the expressions of
MMP2 and MMP9 (Figure 6). In all, in the breast cancer cells,
TPX2 can play a role in promoting proliferation, migration and
invasion through MMP2 and MMP9.
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Breast cancer is the major reason for death in female patients
with cancer [19], and its relapse and migration are the major
factors in affecting its prognosis. The main reason for
unfavorable prognosis in breast cancer patients is due to the
remote metasta of tumor [20,21]. The knowledge about
molecular mechanism of incidence, development and remote
metasta of breast cancer is the preferential choice in all kinds
of treatments [22]. More and more evidences are showing that
microtubule-associated protein TPX2 plays an important role
in nuclear proliferation, cell cycle and formation of spindle
apparatus in mitosis [23–25]. Through mitosis, TPX2 and its
downstream molecules interact with each other and locate in
microtubule-associated proteins formed by spindle apparatus
of Aurora A in mitosis so that to activate the Aurora A kinase
[26,27]. Therefore, TPX2 has been regarded as the oncogene in
many human tumors. However, role of TPX2 in breast cancer
has not yet been reported.
Researches show that TPX2 can promote the formation,
incidence and development of tumors as well as the growth and
remote metasta [28]. Liu et al. reported that downregulated
TPX2 can inhibit the expressions of MMP2 and MMP9
through inhibiting the activation of Akt so as to inhibit the
metasta and invasion of liver cancer cells [29]. The present
study was the ﬁrst to explore the expression of TPX2 in the
breast cancer tissue and tumor-adjacent tissue with results
showing that mRNA and protein expressions of TPX2 were
signiﬁcantly higher in the breast cancer tissue than those in
tumor-adjacent tissue, and that the expressions in different
breast cancer cell lines were also obviously elevated. Down-
regulated TPX2 can signiﬁcantly inhibit the proliferation,
migration and invasion of breast cancer cells. Furthermore, it is
found in the present study that downregulation of TPX2 can
lead to the decrease in expressions of MMP2 and MMP9. In all,
these data show that upregulation of TPX2 in breast cancer
tissue and its effect in promoting proliferation, migration and
invasion of breast cancer cells through upregulating the MMP2
and MMP9 expressions [30].
In conclusion, the results of present study show that TPX2
expression is obviously upregulated in breast cancer and that
TPX2 downregulated by siRNA can inhibit the proliferation,
invasion and migration of breast cancer cells through inhibiting
expressions of MMP2 and MMP9. Nevertheless, the connection
between TPX2 and prognosis, and speciﬁc molecular mecha-
nism still need further research.
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